Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HB0025 plus chemotherapy as first-line treatment for unresectable metastatic colorectal cancer
CTR20254814Phase 2Active
- Sponsor
- Huabo Biopharm
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sotiburafusp alfa in colorectal cancer (CRC), sponsored by Huabo Biopharm. Started Dec 2025; status: active.
02
Drugs
sotiburafusp alfa
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20254814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254814.